- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Imron Aly, JD: Putting Patents in the Purple Book
Imron Aly, JD, partner at Schiff Hardin LLP, discusses the impact of listing patents in the FDA's Purple Book.
Transcript:
How might including patents in the Purple Book affect developers?
For generics point of view, putting patent information in the Purple Book would be a huge improvement to the status quo. Right now, there’s a lot of uncertainty about what patens could be asserted, when they would be asserted, and even how they would be asserted. We’ve heard a lot about the patent dance in literature and publications, but having that listing, much like there’s already that Orange Book for small molecules, would really give guidance to the generics to see what are the patents, what are the expiration dates, and what is a pathway to get to a generic biologic?
I would add from a brand point of view, it would also be very helpful because they would have certainty as well about which patents apply to which products and therefore can put up their own hurdles in terms of what patent information they would like to have listed.
Finally, there is one challenge having information on the Purple Book like the Orange Book, and that is so many biologics patents are process patents, how to make the biologic, or tools to get to the biologic. That’s very different because the Orange Book currently does not allow for listing of process patents, and therefore those aren’t in the Orange Book at all. That would be a big difference to keep an eye out for.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
